Ascendis Pharma A (ASND) Free Cash Flow (2012 - 2026)

Ascendis Pharma A has disclosed Free Cash Flow across 15 years of filings, most recently posting -$9.0 million for Q1 2026.

• Free Cash Flow for Q1 2026 came in at -$9.0 million, up 39.96% year-over-year; the trailing twelve-month figure through Mar 2026 was -$138.5 million (up 41.05% YoY), and the FY2025 annual result was -$146.4 million, up 55.26% from the prior year.
• Free Cash Flow came in at -$9.0 million for Q1 2026 at Ascendis Pharma A, up from -$123.7 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $2.5 million in Q3 2025 to a low of -$166.3 million in Q2 2023.
• The 5-year median for Free Cash Flow is -$96.5 million (2022), against an average of -$87.9 million.
• Across the five-year window, Free Cash Flow plunged 103.56% in 2024 and soared 104.12% in 2025, its largest moves.
• Ascendis Pharma A's Free Cash Flow stood at -$139.6 million in 2022, then soared by 67.23% to -$45.8 million in 2023, then plunged by 103.56% to -$93.2 million in 2024, then sank by 32.79% to -$123.7 million in 2025, then surged by 92.69% to -$9.0 million in 2026.
• The last three Free Cash Flow figures came in at -$9.0 million (Q1 2026), -$123.7 million (Q4 2025), and $2.5 million (Q3 2025), per Business Quant data.